Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Palisade Bio, Inc. announced the appointment of Margery Fischbein to its Board of Directors. Ms. Fischbein, a veteran in Wall Street and the biotech industry, brings expertise in corporate finance, business development, M&A, licensing, and strategic alliance transactions. Her appointment is expected to enhance Palisade Bio's strategy and pipeline of novel therapeutics, particularly in autoimmune, inflammatory, and fibrotic diseases.
Palisade Bio, Inc. (Nasdaq: PALI) closed a $4 million private placement with an institutional investor for 615,242 shares of common stock, intended for development of PALI-2108 and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent. The company issued unregistered warrants for up to 922,863 shares of common stock with a term of seven years and an exercise price of $6.314 per share.
Palisade Bio, a biopharmaceutical company, is raising $4 million through a private placement offering. The company will issue common stock and warrants to an institutional investor at $6.5015 per share. The net proceeds will be used for working capital and general corporate purposes. The closing is expected around May 6, 2024.
Palisade Bio announced the successful completion of an analysis demonstrating the potent anti-inflammatory effects of PALI-2108 in treating Ulcerative Colitis (UC). The study showed the superior efficacy of PALI-2108 compared to the approved PDE4 inhibitor apremilast, positioning it as a next-generation therapeutic option for inflammatory bowel disease. The company is set to begin Phase 1 human clinical trials before the end of the year, with promising results from the study conducted in collaboration with Paraza Pharma, Inc.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.